CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL

Authors: Jianyong Li,[1] Keshu Zhou,[2] Mazyar Shadman,[3,4] Arnon P. Kater,[5] Jennifer Ann Woyach,[6] Talha Munir,[7] Tommi Salmi,[8] Xia Zhao,[9] Haiyi Guo,[10] Tian Tian,[11] Piers E.M. Patten[12,13]

Affiliations: [1]Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China; [2]Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; [3]Lymphoid Malignancies and Immunotherapy, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; [4]University of Washington, Seattle, WA, USA; [5]Department of Hematology, Lymphoma and Myeloma Research Amsterdam, Amsterdam, the Netherlands; [6]Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; [7]Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; [8]BeiGene International GmbH, Basel, Switzerland; [9] BeiGene (Beijing) Co, Ltd, Beijing, China; [10]BeiGene (Shanghai) Co, Ltd, Shanghai, China; [11]BeiGene USA, Inc, San Mateo, CA, USA; [12]Department of Haematological Medicine, Comprehensive Cancer Centre, King's College London, UK; [13]King's College Hospital, London, UK

ABSTRACT

Objective: The combination of venetoclax, the first-generation BCL2 inhibitor, and ibrutinib, a BTK inhibitor, has demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL) (Wierda et al. *J Clin Oncol.* 2021); however, the toxicity profile of this regimen suggests a need for a more tolerable BTK/BCL2 inhibitor combination. Sonrotoclax, a next generation BCL2 inhibitor, is a more selective and more pharmacologically potent inhibitor of BCL2 than venetoclax. In a phase 1 study in patients with treatment-naive (TN) CLL treated with sonrotoclax + zanubrutinib, efficacy data was promising with ORR and 1-year progression-free survival (PFS) rates of 100% and deep responses based on undetectable measurable residual disease at $<10^{-4}$ sensitivity (uMRD4). The most common grade ≥3 TEAE was neutropenia, and no tumor lysis syndrome or cardiac toxicity was observed (Tam et al. *Blood*. 2023). Zanubrutinib, a next-generation BTK inhibitor, significantly improved PFS and had a more tolerable safety profile, including fewer cardiac adverse events vs ibrutinib in a randomized, head-to-head study of patients with CLL/small lymphocytic lymphoma (SLL) (Brown et al. *N Engl J Med*. 2023). Presented here is the design of a phase 3 trial aimed at comparing the efficacy of sonrotoclax + zanubrutinib vs venetoclax + obinutuzumab in patients with TN CLL.

Methods: CELESTIAL-TNCLL (BGB-11417-301; NCT06073821) is a randomized, open-label, phase 3 study. Eligible patients must have previously untreated CLL that requires treatment per 2018 iwCLL criteria, measurable disease by CT/MRI, an ECOG performance score of 0-2, and adequate hematologic and organ function. Approximately 640 patients will be randomized 1:1 to receive either 3 cycles of zanubrutinib monotherapy (320 mg total daily dose, orally), followed by zanubrutinib + sonrotoclax for 12 cycles, or standard venetoclax + obinutuzumab treatment for 12 cycles. Randomization will be stratified by age (<65 vs ≥65 years) and IGHV and del(17p)/*TP53* mutation status. The primary endpoint is PFS as assessed by independent review committee (IRC) according to 2018 iwCLL guidelines with modifications for treatment-related lymphocytosis for patients with CLL (Cheson et al. 2012). Key secondary endpoints include complete response rate (CRR), defined as CR or CR with incomplete hematopoietic recovery, assessed by IRC; rates of uMRD4 in bone marrow and peripheral blood at the first post-treatment follow-up visit based on next-generation sequencing by clonoSEQ®; and overall survival. Other secondary endpoints include PFS as assessed by investigator (INV); CRR by INV; rate of

uMRD4 based on flow cytometry; overall response rate by IRC and INV; duration of response by IRC and INV; patient-reported outcomes; and safety and tolerability. Recruitment is ongoing.